Novartis’ Mayzent (siponimod) Receives EC’s Approval to Treat Patients with Secondary Progressive Multiple Sclerosis with Active Disease

 Novartis’ Mayzent (siponimod) Receives EC’s Approval to Treat Patients with Secondary Progressive Multiple Sclerosis with Active Disease

Novartis’ Mayzent (siponimod) Receives EC’s Approval to Treat Patients with Secondary Progressive Multiple Sclerosis with Active Disease

Shots:

  • The EC’s approval is based on P-III EXPAND study assessing Mayzent vs PBO in patients with SPMS with active disease defined as patients with relapses in the two years prior to the study and/or presence of Gd-enhancing T1 lesions at baseline
  • Results in patients with active disease & in overall population: reduction in three‑month and six‑month CDP (31% and 37% & 21% and 26%) respectively; 79% reduction in T2 lesion volume; 55% reduction in ARR; patients free from Gd enhancing lesions (89% vs 67%); from T2 lesions (57% vs 37%)
  • Mayzent is a sphingosine 1-phosphate receptor modulator, selectively targeting S1P1 and S1P5 receptors and has received the US FDA’s & TGA’s approval in Mar & Nov’2019 respectively

Click here ­to­ read full press release/ article | Ref: Novartis | Image: Business today

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post